^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FPR3 (Formyl Peptide Receptor 3)

    i
    Other names: FPR3, Formyl Peptide Receptor 3, FPRH1, Formyl Peptide Receptor-Like 2, RMLP-R-I, FMLPY, FPRL2, N-Formyl Peptide Receptor 3, FMLP-Related Receptor II, FMLP-R-II, FML2_HUMAN, FPRH2
    Associations

    News

    Trials
    1m
    Sig27 stratifies prostate cancer recurrence via assessing tumor's immunosuppressive properties. (PubMed, Endocr Relat Cancer)
    Notably, Sig27IMG stratified patients with a poor prognosis risk in these 17 cancer types. In summary, Sig27 and its derivative panel, Sig27IMG, offer a robust assessment of PC recurrence, highlighting immunosuppressive features mediated by TAMs, dendritic cells, and endothelial cells across multiple cancer types.
    Journal • IO biomarker
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAMP3 (Lysosomal Associated Membrane Protein 3) • CD96 (CD96 Molecule) • FPR3 (Formyl Peptide Receptor 3)
    4ms
    FPR3 orchestrates macrophage polarization in breast cancer: multi-omics dissection of prognostic relevance and therapeutic targeting. (PubMed, Cancer Cell Int)
    These findings underscore the profound infiltration of FPR3 + macrophages in breast cancer patients with adverse prognoses, highlighting FPR3 as a potential therapeutic target for intervening breast cancer aggressiveness.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • FPR3 (Formyl Peptide Receptor 3)
    |
    HER-2 positive
    7ms
    Decoding the impact of MMP1+ malignant subsets on tumor-immune interactions: insights from single-cell and spatial transcriptomics. (PubMed, Cell Death Discov)
    Inhibition of MMP1 in vitro demonstrated reduced cell invasion, stemness, and proliferation, while increasing reactive oxygen species levels and promoting apoptosis. Our findings position MMP1 as a key player in the "tumor-immune" vicious cycle and a promising therapeutic target to enhance anti-tumor responses and improve patient outcomes.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • ANXA1 (Annexin A1) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • MMP1 (Matrix metallopeptidase 1) • CXCL16 (C-X-C Motif Chemokine Ligand 16) • FPR3 (Formyl Peptide Receptor 3)
    8ms
    Redirecting cytotoxic lymphocytes to breast cancer tumors via metabolite-sensing receptors. (PubMed, bioRxiv)
    Based on Perturb-seq and functional investigations, GPR183 also enhances effector functions, such that engineering NK and CAR NK cells to express GPR183 enhances their ability to migrate to, infiltrate, and control breast cancer tumors. Our study uncovered metabolite-based tumor immune recruitment mechanisms, opening avenues for spatially targeted cell therapies.
    Journal
    |
    FPR3 (Formyl Peptide Receptor 3) • GPR183 (G Protein-Coupled Receptor 183)
    9ms
    A novel multigene panel (Sig27) robustly predicts poor prognosis of renal cell carcinoma via high-level associations with immunosuppressive features. (PubMed, BJC Rep)
    Sig27 is a novel and effective pan-RCC biomarker with high-level associations with RCC immunosuppressive features.
    Journal
    |
    LAMP3 (Lysosomal Associated Membrane Protein 3) • FPR3 (Formyl Peptide Receptor 3)
    11ms
    Function of formyl peptide receptor 2 in adriamycin resistance of breast cancer. (PubMed, Exp Biol Med (Maywood))
    p-ERK5 and p-AKT in breast cancer cells was significantly reduced after FPRL2 knocked down. In Conclusion, FPRL2 mediates Adriamycin resistance in breast cancer cells, and knockdown of FPRL2 increased apoptosis and decreased Adriamycin resistance in breast cancer cells.
    Journal
    |
    FPR3 (Formyl Peptide Receptor 3)
    |
    doxorubicin hydrochloride
    1year
    Pan-cancer analysis and experimental validation of FPR3 as a prognostic and immune infiltration-related biomarker for glioma. (PubMed, Front Genet)
    The potential biological relevance of FPR3 was confirmed in glioma, and it was shown to have significant involvement in the processes of glioma growth, immune infiltration, and metastasis. Our results imply a potential association of FPR3 with tumor immunity, indicating its viability as a prognostic indicator in glioma.
    Journal • Tumor mutational burden • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FPR3 (Formyl Peptide Receptor 3)
    over1year
    Machine learning algorithms for predicting glioma patient prognosis based on CD163+FPR3+ macrophage signature. (PubMed, NPJ Precis Oncol)
    The risk score of this model consistently and effectively predicted overall survival, surpassing the accuracy of conventional clinical factors and 100 previously published signatures. Consequently, the CD163+FPR3+ macrophage-related score shows potential as a prognostic biomarker for glioma patients.
    Journal • Machine learning
    |
    CD163 (CD163 Molecule) • FPR3 (Formyl Peptide Receptor 3)
    |
    CD163 expression
    over1year
    Identification of crucial genes through WGCNA in the progression of gastric cancer. (PubMed, J Cancer)
    Immunohistochemical results confirmed that C1QB, FCER1G, FPR3 and TYROBP were significantly associated with disease progression in GC. Our study identified that C1QB, FCER1G, FPR3 and TYROBP played important roles in the progression of GC, and their specific mechanisms are worth further study.
    Journal • IO biomarker
    |
    FCER1G (Fc Fragment Of IgE Receptor Ig) • C1QB (Complement C1q B Chain) • FPR3 (Formyl Peptide Receptor 3) • TYROBP (Transmembrane Immune Signaling Adaptor TYROBP)
    over1year
    MiR-6839-5p inhibits cell proliferation, migration and invasion; a possible correlation with the suppressing VEGFA expression in human chondrosarcoma cells. (PubMed, Discov Oncol)
    Furthermore, miR-6839-5p inhibitor can restore or partially restore the expression value of the above four genes. The analysis results of miRNA target gene prediction database indicated VEGFA was the most likely direct target gene of miR-6839-5p.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • FPR3 (Formyl Peptide Receptor 3) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    BCL2 expression • VEGFA expression
    over1year
    FPR3 reprograms glycolytic metabolism and stemness in gastric cancer via calcium-NFATc1 pathway. (PubMed, Cancer Lett)
    Additionally, NFATc1 directly binds to the sex determining region Y-box 2 (SOX2) promoter and modifies stemness in GC. In conclusion, our work illustrated that FPR3 played a negative role in GC progression by modulating NFATc1-mediated glycolysis and stemness in a calcium-dependent manner, providing potential insights into cancer therapy.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • NOTCH3 (Notch Receptor 3) • SOX2 • NFATC1 (Nuclear Factor Of Activated T Cells 1) • FPR3 (Formyl Peptide Receptor 3)
    |
    NOTCH3 expression
    almost2years
    Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapy. (PubMed, PLoS One)
    The study also found that Tregs had a dense communication network with cluster two, and that certain ligand-receptor pairs, including SPP1/CD44, HLA-E/KLRC2, HLA-E/KLRK1, ANXA1/FPR3, and CXCL9/FCGR2A, had notable changes after the therapy. These changes in gene expression and cell interactions may have implications for the role of Tregs in the TME and in response to Nivolumab therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • LAG3 (Lymphocyte Activating 3) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • LY9 (Lymphocyte Antigen 9) • ANXA1 (Annexin A1) • HLA-E (Major Histocompatibility Complex, Class I, E) • FCGR2A (Fc fragment of IgG receptor IIa) • FOXP3 (Forkhead Box P3) • GZMA (Granzyme A) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • FPR3 (Formyl Peptide Receptor 3) • KLRC2 (Killer Cell Lectin Like Receptor C2) • NKG2D (killer cell lectin like receptor K1)
    |
    PD-1 expression • LAG3 expression • CTLA4 expression
    |
    Opdivo (nivolumab)